Status:
UNKNOWN
Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborating Sponsors:
Peking University First Hospital
Peking Union Medical College Hospital
Conditions:
Hypertension
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.
Detailed Description
EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin on vascular function protection in hypertensive patients at low/moderate cardiovascular risk.
Eligibility Criteria
Inclusion
- All patients must meet the hypertension with low or moderate cardiovascular risk following 2010 Guidelines for prevention and treatment of hypertension in China
Exclusion
- Secondary Hypertension
- Women who are pregnant or lactating
- History of mental instability, or major psychiatric illness not adequately controlled and stable on therapy
- Type 2 Diabetes
- Active liver disease or impaired liver function tests
- Impaired renal function
- Uncontrolled cardiac arrhythmia
- Patient who is unable to give informed consent
- Any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2016
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT02254824
Start Date
October 1 2013
End Date
October 1 2016
Last Update
October 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital
Beijing, Beijing Municipality, China, 100037